SMAD3 and myeloproliferative disorder: The current MPN therapeutic ruxolitinib decreased the fibrosis induced by BM-MSCs isolated from MPN patients, but combined therapy with inhibitors of the TGFβ/SMAD3 signaling pathway had a synergistic effect on fibrosis (Supplementary Fig. 6e).